[go: up one dir, main page]

USRE40882E1 - Antiviral nasal drops comprising recombinant interferon a biocompatible polymer and an antioxidant - Google Patents

Antiviral nasal drops comprising recombinant interferon a biocompatible polymer and an antioxidant Download PDF

Info

Publication number
USRE40882E1
USRE40882E1 US11/256,624 US25662499D USRE40882E US RE40882 E1 USRE40882 E1 US RE40882E1 US 25662499 D US25662499 D US 25662499D US RE40882 E USRE40882 E US RE40882E
Authority
US
United States
Prior art keywords
amount
antioxidant
interferon
genetically engineered
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US11/256,624
Inventor
Petr Jakovlevich Gaponyuk
Elena Alexeevna Markova
Iliya Alexandrovich Markov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of USRE40882E1 publication Critical patent/USRE40882E1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Definitions

  • the present invention can be used in pharmacology specifically in the preparation of interferon-containing compositions, which are capable of conserving their biological activity and can be administered intranasally, e.g. in the preparation of nasal drops.
  • Interferon-containing preparations in addition to antiviral effects, cause strong immunomodulatory effects that induce several positive homeostatic shifts, antitumour effects, etc. (RU, Application 940942742 C1. A 61 K 38/21, 1997, RU, patent 20957544, C1. A 61 K 38/21, 1996).
  • Medicines prepared from leukocytes or any other component of human blood are potentially hazardous and can transmit viral infection (hepatitis, herpes virus, cytomegalovirus, AIDS, slow infections etc.).
  • interferons have efficacy can be increased by using appropriate drug forms (with account taken of the specific pathogenetic features of the diseases) designed to deliver high concentrations of interferon to the focus of viral infection.
  • appropriate drug forms with account taken of the specific pathogenetic features of the diseases
  • interferon causes antiviral and immunomodulatory effects without cytostatic or other side effects.
  • the closest analogue of this invention in terms of the nature of the drug and achieved result, is an antiviral drug form for intranasal administration containing human interferon, a biocompatible polymer (6% Polyglucin), and a buffer mixture with the following contents of ingredients per ml solution.
  • the main idea of this invention was to develop of an antiviral drug form (nasal drops) containing a genetically engineered interferon, which would allow a prolonged contact with nasal mucous, act topically at the site of primary invasion and reproduction of influenza and other respiratory viruses, be easily absorbable, and have an optimal viscosity permitting the drug to spread over the mucous and be retained on it for a long time.
  • an antiviral drug (nasal drops) containig containing a liquid interferon preparation (a genetically engineered alpha, beta or gamma interferon with viscosity of (1.1 ⁇ 30.0)*10 10 ⁇ 3 Pascal.second).
  • the antiviral drug contains a biocompatible polymer, antioxidant, and buffer mixture with the following contents of ingredients per ml buffer mixture:
  • TRILON B® (disodium salt of ethylenediaminetetraacetic acid (“EDTA”)) is used as an antioxidant, and polyvinylpyrrolidone and/or polyethylene oxide is used as a biocompatible polymer.
  • the drug described here contains polyvinylpyrrolidone and polyethylene oxide at a ratio of 1:1-50.
  • Variant 1 The technology of manufactured this drug (nasal drops) is the same for all variants described below.
  • TRILON B® sodium salt of EDTA
  • Each milliliter of the buffer mixture contains:
  • Variant 2 Proceed as described under Variant 1.
  • Each milliliter of the buffer mixture contains:
  • Variant 3 Proceed as described under Variant 1.
  • Each milliliter of the buffer mixture contains:
  • the antiviral drug obtained as described in the previous section has the appearance of a clear liquid whose viscosity differs between variants. Laboratory tests performed on cultured animal cells showed that the drug is not toxic and fully conserves its antiviral activity.
  • the drug is safe, well-tolerated, and does not induce the formation of anti-interferon antibodies. It is administrated in nasal drops for treating acute respiratory disease and influence.
  • the drug is administered intranasally two times a day (2-3 drops into each nostril) during the whole period of contact with a patient (each drop is equivalent to 500 IU).
  • the drug is administrated at dose of 2-3 drops into each nostril every 3-4 hours for 5 days.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention can be used in pharmacology specifically in the preparation of interferon-containing compositions, which are capable of conserving their biological activity and can be administered intranasally, e.g. in the preparation of nasal drops. This invention essentially refers to an antiviral agent in the form of nasal drops that contains a genetically engineered alpha, beta or gamma interferon with a viscosity of (1.1−30.0)* 10 10−3 Pascal .second, a biocompatible polymer and a buffer mixture. The agent may further include an antioxidant, and the ingredients are contained in the following amounts per ml buffer mixture: 1,000 to 5,000 500,000 IU of genetically engineered interferon; 0.005 to 0.714 g of biocompatible polymer; and 0.0001 to 0.0008 g of an antioxidant. TRILON B® (disodium salt of EDTA) is used as the antioxidant, whereas polyvinylpyrrolidone and/or polyethylene oxide is (are) used as the biocompatible polymer(s) at polyvinylpyrrolidone/polyethylene oxide ratio of 1:1-50.

Description

CROSS REFERENCES TO RELATED APPLICATIONS
The present application claims the benefit of priority of PCT International Application No. PCT/RU99/00320, filed on Sep. 6, 1999, which claims priority from Russian Federation patent application No. 9910066, filed Mar. 16, 1999.
FIELD OF THE INVENTION
The present invention can be used in pharmacology specifically in the preparation of interferon-containing compositions, which are capable of conserving their biological activity and can be administered intranasally, e.g. in the preparation of nasal drops.
BACKGROUND OF THE INVENTION
Medicines containing interferons (natural, recombinant or genetically engineered) are widely used. Interferon-containing preparations, in addition to antiviral effects, cause strong immunomodulatory effects that induce several positive homeostatic shifts, antitumour effects, etc. (RU, Application 940942742 C1. A 61 K 38/21, 1997, RU, patent 20957544, C1. A 61 K 38/21, 1996).
In Russia, natural human interferons derived from leukocytes have been widely used for the treatment and prevention of influenza and acute viral respiratory infections (AVRI) since the late 1960s. This interferon was manufactured from expensive donor blood leukocyte preparations (RU, patent 2033180, C1. A 61 K 38/21, 1995. SU, Inventor's Certificate 297296, C1. A 61 K 36/21, 1977. RU, patent 2108804, C1. A 61 K 38/21, 1996).
Medicines prepared from leukocytes or any other component of human blood are potentially hazardous and can transmit viral infection (hepatitis, herpes virus, cytomegalovirus, AIDS, slow infections etc.).
Because of this, recombinant and genetically engineered interferon preparations of the highest purification (up to 98% pure) are increasingly used for clinical purposes (FS 42-3279-96, VFS 42-2989-97, RU, Patent 2073522, C1. A 61 38/21, 1997, Ershov, F.I., Sistema interferona v norme i pri patologii (The Interferon System under Normal and Pathological Conditions); Moscow: Medicina, 1966, p.216.
These preparations are effective in treating oncological diseases by parenteral administration of high doses (3-10 million IU or more per 24 h) in repeated long courses. However, such doses often cause side effects, such as disorders haemopoiesis, suppression of the immune system, formation of anti-interferon antibodies etc.
However, the recent experience with clinical administration of interferons suggests that their efficacy can be increased by using appropriate drug forms (with account taken of the specific pathogenetic features of the diseases) designed to deliver high concentrations of interferon to the focus of viral infection. After such an administration, interferon causes antiviral and immunomodulatory effects without cytostatic or other side effects. This makes it expedient to develop various drug forms containing interferons designed for topical administration (suppositories, ointments, drops, aerosols, etc.) The closest analogue of this invention, in terms of the nature of the drug and achieved result, is an antiviral drug form for intranasal administration containing human interferon, a biocompatible polymer (6% Polyglucin), and a buffer mixture with the following contents of ingredients per ml solution.
Interferon (1-6.6) .10 IU
Biocompatible polymer (Polyglucin) 5-30
Buffer mixture pH 7.0-7.6 in solution

(RU. Patent 2095081, Cl. A 61 K 38/21, 1977).
However, intranasal drug forms containing recombinant or genetically engineered interferons have not been developed in Russia.
SUMMARY OF THE INVENTION
The main idea of this invention was to develop of an antiviral drug form (nasal drops) containing a genetically engineered interferon, which would allow a prolonged contact with nasal mucous, act topically at the site of primary invasion and reproduction of influenza and other respiratory viruses, be easily absorbable, and have an optimal viscosity permitting the drug to spread over the mucous and be retained on it for a long time.
To solver solve this problem, we developed an antiviral drug (nasal drops) containig containing a liquid interferon preparation (a genetically engineered alpha, beta or gamma interferon with viscosity of (1.1−30.0)*10 10−3 Pascal.second). The antiviral drug contains a biocompatible polymer, antioxidant, and buffer mixture with the following contents of ingredients per ml buffer mixture:
Genetically engineered interferon 1000-50,000 500,000 IU
Biocompatible polymer 0.005-0.714 g
Antioxidant 0.0001-0.0008 g
TRILON B® (disodium salt of ethylenediaminetetraacetic acid (“EDTA”)) is used as an antioxidant, and polyvinylpyrrolidone and/or polyethylene oxide is used as a biocompatible polymer. The drug described here contains polyvinylpyrrolidone and polyethylene oxide at a ratio of 1:1-50.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Variant 1. The technology of manufactured this drug (nasal drops) is the same for all variants described below. Prepare solutions of the following ingredients in separate containers: 50% polyethylene oxide, 6% polyvinylpyrrolidone and 10% aqueous TRILON B® (disodium salt of EDTA). Filter the solutions. Use phosphate-buffered saline as a solvent. Add these solutions to a manufacturing vessel in the specified sequence, and sterilize. Then add genetically engineered interferon. Mix the ingredients. Dispense the solution into appropriate containers, hermetically seal and label.
Suggested composition of the antiviral drug:
Each milliliter of the buffer mixture contains:
Genetically engineered interferon beta 500,000 IU
Polyvinylpyrrolidone 0.014 g
Polyethylene oxide 0.7 g
TRILON B ® (disodium salt of EDTA) 0.0008 g
Viscosity of solution 30.0*10 10−3 Pascal.second
Variant 2: Proceed as described under Variant 1.
Suggested composition of the antiviral drug:
Each milliliter of the buffer mixture contains:
Genetically engineered interferon alpha 10,000 IU
Polyvinylpyrrolidone 0.01 g
Polyethylene oxide 0.1 g
TRILON B ® (disodium salt of EDTA) 0.0004 g
Viscosity of solution 3.0*10 10−3 Pascal.second
Variant 3: Proceed as described under Variant 1.
Suggested composition of the antiviral drug:
Each milliliter of the buffer mixture contains:
Genetically engineered interferon gamma 1,000 IU
Polyvinylpyrrolidone 0.05 g
TRILON B ® (disodium salt of EDTA) 0.0001 g
Viscosity of solution 1.1*10 10−3 Pascal.second

Feasibility of Industrial-Scale Manufacture
The antiviral drug (nasal drops) obtained as described in the previous section has the appearance of a clear liquid whose viscosity differs between variants. Laboratory tests performed on cultured animal cells showed that the drug is not toxic and fully conserves its antiviral activity.
Clinical tests on 59 volunteers of 18-20 years showed that the drug is safe, well-tolerated, and does not induce the formation of anti-interferon antibodies. It is administrated in nasal drops for treating acute respiratory disease and influence. For prophylaxis of respiratory diseases, the drug is administered intranasally two times a day (2-3 drops into each nostril) during the whole period of contact with a patient (each drop is equivalent to 500 IU). For the treatment of influenza, the drug is administrated at dose of 2-3 drops into each nostril every 3-4 hours for 5 days.

Claims (10)

1. An antiviral drug presented as nasal drops comprising genetically engineered alpha, beta or gamma interferon, at least one biocompatible polymer selected from the group consisting of polyvinyl pyrrolidone and polyethylene oxide, and a biocompatible antioxidantthe drug viscosity being 11-300 Pascal second , said antioxidant being TRILON B® (disodium salt of ethylenediaminetetraacetic acid), wherein the antiviral drug comprises per ml of a buffered saline solution:
the genetically engineered alpha, beta, or gamma interferon in an amount of 1,000-500,000 IU;
the at least one biocompatible polymer in an amount of 0.005-0.714 g; and
the antioxidant in an amount of 0.0001-0.0008 g.
2. The antiviral drug of claim 1 wherein the antioxidant is TRILON B® (disodium salt of ethylenediaminetetraacetic acid).
3. The antiviral drug of claim 1 or claim 2 comprising polyvinyl pyrrolidone and polyethylene oxide in a ratio of 1:1 to 1:50.
4. An antiviral drug presented as nasal drops comprising genetically engineered alpha, beta or gamma interferon, at least one biocompatible polymer selected from the group consisting of polyvinyl pyrrolidone and polyethylene oxide, and a biocompatible antioxidant, said antioxidant being TRILON B® (disodium salt of ethylenediaminetetraacetic acid), wherein the antiviral drug comprises per ml of a buffered saline solution:
a.the genetically engineered alpha, beta or gamma interferon in an amount of 1,000-300,000 IU;
b.the at least one biocompatible polymer selected from the group consisting of polyvinyl pyrrolidone and polyethylene oxidein an amount of 0.005-0.714 g; and
c.the antioxidant in an amount of 0.0001-0.0008 gthe drug viscosity being 11-300 Pascal second .
5. The antiviral drug of claim 4 wherein the antioxidant is TRILON B® (disodium salt of ethylenediaminetetraacetic acid).
6. The antiviral drug of claim 4 or claim 5 comprising polyvinyl pyrrolidone and polyethylene oxide.
7. The antiviral drug of claim 4 or claim 5 comprising polyvinyl pyrrolidone and polyethylene oxide in a ratio of 1:1 to 1:50.
8. The antiviral drug of claim 1, wherein said drug comprises per ml of buffered saline solution:
genetically engineered interferon beta in the amount of 500,000 IU,
polyvinylpyrrolidone in the amount of 0.014 g,
polyethylene oxide in the amount of 0.7 g, and
Trilon B® in the amount of 0.0008 g.
9. The antiviral drug of claim 1, wherein said drug comprises per ml of buffered saline solution:
genetically engineered interferon alpha in the amount of 10,000 IU,
polyvinylpyrrolidone in the amount of 0.01 g,
polyethylene oxide in the amount of 0.1 g, and
Trilon B® in the amount of 0.0004 g.
10. The antiviral drug of claim 1, wherein said drug comprises per ml of buffered saline solution:
genetically engineered interferon gamma in the amount of 1,000 IU,
polyvinylpyrrolidone in the amount of 0.05 g, and
Trilon B® in the amount of 0.0001 g.
US11/256,624 1999-01-25 1999-09-06 Antiviral nasal drops comprising recombinant interferon a biocompatible polymer and an antioxidant Expired - Lifetime USRE40882E1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU99100666A RU2140285C1 (en) 1999-01-25 1999-01-25 Antiviral agent - nasal drops "grippferon"
PCT/RU1999/000320 WO2000054798A1 (en) 1999-01-25 1999-09-06 Antiviral agent in the form of nose drops

Publications (1)

Publication Number Publication Date
USRE40882E1 true USRE40882E1 (en) 2009-08-25

Family

ID=20214625

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/936,470 Ceased US6635243B1 (en) 1999-01-25 1999-09-06 Antiviral nasal drops comprising recombinant interferon a biocompatible polymer and an antioxidant
US11/256,624 Expired - Lifetime USRE40882E1 (en) 1999-01-25 1999-09-06 Antiviral nasal drops comprising recombinant interferon a biocompatible polymer and an antioxidant

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/936,470 Ceased US6635243B1 (en) 1999-01-25 1999-09-06 Antiviral nasal drops comprising recombinant interferon a biocompatible polymer and an antioxidant

Country Status (14)

Country Link
US (2) US6635243B1 (en)
EP (1) EP1314436B1 (en)
CN (1) CN1166405C (en)
AT (1) ATE434441T1 (en)
AU (1) AU776182B2 (en)
CA (1) CA2372099C (en)
CY (1) CY1110352T1 (en)
DE (1) DE69941033D1 (en)
DK (1) DK1314436T3 (en)
ES (1) ES2329204T3 (en)
PT (1) PT1314436E (en)
RU (1) RU2140285C1 (en)
UA (1) UA72916C2 (en)
WO (1) WO2000054798A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2187330C1 (en) * 2000-12-18 2002-08-20 Гапонюк Петр Яковлевич Antiviral agent
RU2195315C2 (en) * 2001-02-28 2002-12-27 Московский областной научно-исследовательский клинический институт Method of treatment of children of first year life with acute respiratory viral disease
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
RU2220738C1 (en) * 2002-08-30 2004-01-10 Гапонюк Петр Яковлевич Agent for rhinitis treatment
RU2220739C1 (en) * 2002-08-30 2004-01-10 Гапонюк Петр Яковлевич Intranasal agent
RU2220740C1 (en) * 2002-08-30 2004-01-10 Гапонюк Петр Яковлевич Agent for treatment of allergic rhinitis and allergic conjunctivitis
MXPA06014215A (en) * 2004-06-07 2007-05-04 Nastech Pharm Co Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides.
EP1951285A2 (en) * 2005-11-18 2008-08-06 Ares Trading S.A. Interferon in influenza
EP2464406B1 (en) * 2009-08-10 2016-10-26 Proviflo, LLC Catheter lock solutions utilizing tocopherol and mid-chain fatty acids
RU2437676C1 (en) * 2010-07-27 2011-12-27 Илья Александрович Марков Antiviral medication - nasal drops
RU2488405C1 (en) * 2012-07-17 2013-07-27 Илья Александрович Марков Drug herpferon-2 possessing antiviral, anti-inflammatory, immunomodulatory and analgesic action for local and external application
RU2554495C2 (en) * 2013-03-11 2015-06-27 Илья Александрович Марков Cytokine-containing medication, possessing antiviral, antimicrobial, immunomodulating and anti-inflammatory action for prevention and treatment of infection diseases
WO2016169571A1 (en) * 2015-04-20 2016-10-27 Ghaleb Haider Abbas Pharmaceutical product for treatment & prophylaxis of viral/ microbial infection
US10456570B2 (en) 2015-06-11 2019-10-29 Proviflo, Llc Graft-port hemodialysis systems, devices, and methods
RU2768656C1 (en) * 2021-09-10 2022-03-24 Илья Александрович Марков Antiviral agent in liquid form and method for its preparation

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647454A (en) * 1982-03-17 1987-03-03 Inter-Yeda Ltd. Stable interferon β composition and a method of stabilizing interferon β
US4710376A (en) 1985-02-01 1987-12-01 Interferon Sciences, Inc. Topical therapeutic composition containing oxidation inhibitor system
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US5059418A (en) * 1989-09-20 1991-10-22 The Administrators Of The Tulane Educational Fund Synergistic effect of human recombinant interferon-beta on halogenated pyrimidines
WO1993021229A1 (en) 1992-04-15 1993-10-28 Amgen Inc. Methods and compositions for the treatment of diseases with interferon while reducing side effects
RU2020967C1 (en) 1991-06-10 1994-10-15 Научно-производственное объединение прикладной механики Device for vacuum massage
RU2022562C1 (en) 1992-05-06 1994-11-15 Рубальский Олег Васильевич Method of treatment of skin viral infection and mucous membranes
RU2033180C1 (en) 1991-07-04 1995-04-20 Научно-исследовательский институт эпидемиологии и микробиологии им.Н.Ф.Гамалеи Method for rehabilitation of patients having radiation affection
RU2057544C1 (en) 1992-02-11 1996-04-10 Научно-производственное предприятие "Тринита" Preparation for treatment of viral, chlamydiosis and bacterial infections
RU2073522C1 (en) 1995-07-20 1997-02-20 Олег Васильевич Рубальский Medicinal preparation having antivirus effect
RU2077336C1 (en) 1994-12-06 1997-04-20 Государственный научно-исследовательский институт прикладной микробиологии Genetic-engineering gamma-interferon preparation
RU2095081C1 (en) 1991-12-13 1997-11-10 Акционерное общество "Биофа" Antiviral pharmaceutical composition
RU2097061C1 (en) 1992-02-11 1997-11-27 Научно-производственное предприятие "Тринита" Medicinal preparation for viral infection treatment
RU2108804C1 (en) 1997-06-24 1998-04-20 Общество с ограниченной ответственностью "Свет Софт Био" Preparation "locferon" for treatment and prophylaxis of viral diseases and a method of its preparing

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476116A (en) * 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
JPS59163313A (en) * 1983-03-09 1984-09-14 Teijin Ltd Peptide hormone composition for nasal administration
US4857316A (en) * 1984-10-03 1989-08-15 Syntex (U.S.A.) Inc. Synergistic antiviral composition
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination
CA2033725C (en) * 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
RU2020957C1 (en) * 1991-05-14 1994-10-15 Нестерова Ирина Вадимовна Method of treating persisting respiratory virus diseases
DE19733651A1 (en) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Aqueous aerosol preparations containing biologically active marrow molecules and processes for producing corresponding aerosols

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647454A (en) * 1982-03-17 1987-03-03 Inter-Yeda Ltd. Stable interferon β composition and a method of stabilizing interferon β
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4710376A (en) 1985-02-01 1987-12-01 Interferon Sciences, Inc. Topical therapeutic composition containing oxidation inhibitor system
US5059418A (en) * 1989-09-20 1991-10-22 The Administrators Of The Tulane Educational Fund Synergistic effect of human recombinant interferon-beta on halogenated pyrimidines
RU2020967C1 (en) 1991-06-10 1994-10-15 Научно-производственное объединение прикладной механики Device for vacuum massage
RU2033180C1 (en) 1991-07-04 1995-04-20 Научно-исследовательский институт эпидемиологии и микробиологии им.Н.Ф.Гамалеи Method for rehabilitation of patients having radiation affection
RU2095081C1 (en) 1991-12-13 1997-11-10 Акционерное общество "Биофа" Antiviral pharmaceutical composition
RU2057544C1 (en) 1992-02-11 1996-04-10 Научно-производственное предприятие "Тринита" Preparation for treatment of viral, chlamydiosis and bacterial infections
RU2097061C1 (en) 1992-02-11 1997-11-27 Научно-производственное предприятие "Тринита" Medicinal preparation for viral infection treatment
WO1993021229A1 (en) 1992-04-15 1993-10-28 Amgen Inc. Methods and compositions for the treatment of diseases with interferon while reducing side effects
RU2022562C1 (en) 1992-05-06 1994-11-15 Рубальский Олег Васильевич Method of treatment of skin viral infection and mucous membranes
RU2077336C1 (en) 1994-12-06 1997-04-20 Государственный научно-исследовательский институт прикладной микробиологии Genetic-engineering gamma-interferon preparation
RU2073522C1 (en) 1995-07-20 1997-02-20 Олег Васильевич Рубальский Medicinal preparation having antivirus effect
RU2108804C1 (en) 1997-06-24 1998-04-20 Общество с ограниченной ответственностью "Свет Софт Био" Preparation "locferon" for treatment and prophylaxis of viral diseases and a method of its preparing

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Inventor's Certificate 297296, Ershov F.L., Medicina, p. 216 (1996).

Also Published As

Publication number Publication date
EP1314436A1 (en) 2003-05-28
CA2372099C (en) 2011-10-18
US6635243B1 (en) 2003-10-21
ATE434441T1 (en) 2009-07-15
ES2329204T3 (en) 2009-11-23
DK1314436T3 (en) 2009-11-02
UA72916C2 (en) 2005-05-16
EP1314436B1 (en) 2009-06-24
CA2372099A1 (en) 2000-09-21
EP1314436A4 (en) 2003-05-28
CY1110352T1 (en) 2015-04-29
CN1166405C (en) 2004-09-15
WO2000054798A1 (en) 2000-09-21
AU5766599A (en) 2000-10-04
DE69941033D1 (en) 2009-08-06
PT1314436E (en) 2009-09-28
CN1344165A (en) 2002-04-10
RU2140285C1 (en) 1999-10-27
AU776182B2 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
USRE40882E1 (en) Antiviral nasal drops comprising recombinant interferon a biocompatible polymer and an antioxidant
JP2011225599A (en) Human serum albumin-free stabilized interferon liquid formulation
RU2073522C1 (en) Medicinal preparation having antivirus effect
US20030170207A1 (en) Stable aqua formulation of interferon, the preparation method and the uses thereof
CN112386595A (en) Pharmaceutical composition for treating viral infection of respiratory system
EP2604264B1 (en) Pharmaceutical composition for treating viral diseases
CN111671886A (en) A drug combination for preventing high-risk susceptible population from contracting coronavirus or developing coronavirus-infected disease and use thereof
SK129999A3 (en) Pharmaceutical composition, preparation process and use thereof
US4828830A (en) Method and composition for prophylaxis and treatment of viral infections
CA1336491C (en) Antiviral pharmaceutical composition
US9839672B1 (en) Treatment of thrombocytopenia using orally administered interferon
Tyrrell Interferons and their clinical value
RU2554495C2 (en) Cytokine-containing medication, possessing antiviral, antimicrobial, immunomodulating and anti-inflammatory action for prevention and treatment of infection diseases
RU2162337C1 (en) Antiviral agent nasal drops
CN120549858A (en) Recombinant human interferon α1b solution and its preparation method and application
RU2833350C1 (en) Intranasal antiviral agent
JPH06298665A (en) Antiviral agent
JPH0240649B2 (en)
RU2744854C1 (en) Liquid dosage form for treating and preventing influenza and sars
US20210322480A1 (en) Platelet-Rich Plasma Compositions and Related Methods
US20030147850A1 (en) Composition and methods for potentiating therapeutic effects of interferons
RU2242243C2 (en) Compositions and methods for potentiating therapeutic effects of interferons
CA1295240C (en) Biologically stable interferon compositions
JPS62185030A (en) Interferon pharmaceutical for nasotracheal administration
JPS63198635A (en) Antiviral agent against aids causing virus

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12

SULP Surcharge for late payment

Year of fee payment: 11